A Phase 1 interventional study of Risankizumab in Healthy Volunteer, sponsored by AbbVie. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive a single dose of Risankizumab On-Body Injector (OBI) produced by new process on Day 1.
Drug: Risankizumab
Participants will receive a single dose of Risankizumab On-Body Injector (OBI) produced by current process on Day 1.
Drug: Risankizumab
Subcutaneous Injection
Also known as: SKYRIZI, ABBV-066
Maximum Observed Plasma Concentration (Cmax) of Risankizumab
Maximum observed plasma concentration (Cmax) of Risankizumab
Time frame: Up to approximately 140 days
Time to Cmax (Tmax) of Risankizumab
Tmax of Risankizumab
Time frame: Up to approximately 140 days
Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab
Apparent terminal phase elimination rate constant (β) of Risankizumab
Time frame: Up to approximately 140 days
Terminal Phase Elimination Half-life (t1/2) of Risankizumab
Terminal phase elimination half-life (t1/2) of Risankizumab
Time frame: Up to approximately 140 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUCt) of Risankizumab
AUCt of Risankizumab
Time frame: Up to approximately 140 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCinf) of Risankizumab
AUCinf of Risankizumab
Time frame: Up to approximately 140 days
Number of Anti-drug antibody (ADA) Titers
Incidence and concentration of anti-drug antibodies
Time frame: Up to approximately 140 days
Number of Participants Experiencing Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment
Time frame: Up to approximately 140 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie